runncoach,
There is only one patent pending. It is a US patent application that was rejected in 2012, resubmitted as an RCE in 2013, and is now sitting in the USPTO queue in their current backlog of RCE applications.
The European patent was withdrawn in 2013 when nobody paid the annual fee to keep it active.
The WIPO "patent application" is just a reference to the USPTO RCE application.
Therefore, there is no "patent news" coming any time soon -- could be YEARS, literally, as many RCE applications are sitting in a backlog that has been a news story for quite some time.
And the other "catalyst" that is supposed to trigger the completion of the "takeover," the Dignyte/eWellness merger, failed to execute by the deadline of 03/31/2014. This reinforces the notion that the word "contemplates" in a LOI doesn't mean much. They also used the word "contemplates" to describe the term sheet financing back in 2012 that was supposed to keep the company alive but also failed to materialize.
Personally, I think the MJ rumor had more to it than the takeover/merger rumor. Certainly, Wall Street thought so. But I think we can all agree that neither rumor holds up after five minutes of real DD.
As for "commercial success," the test never had it and never will, IMO. DR-70 is used in laboratory research and referenced in some abstracts, but I doubt UNI will have success selling the test in Asia or anywhere else. I doubt anyone will even TRY to manufacture and sell a generic DR-70 test after June 3rd when the patent expires. That includes GCDx. I don't think the GCDx business model has much to do with actually selling the test -- I think their business model, like MacLellan's apparent business model, is "get funding, pay the officers a big salary, release a few PR's, make excuses for poor revenues, repeat until the funding runs out."
